Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

Figure 1

Mouse model (LLC in C57/Bl6) study design (A) and observed tumor growth inhibition (B). Mice received the indicated treatments when tumors had reached volume of 81 mm3 to 137 mm3 7 days after implantation. Cisplatin 4 mg/kg was administered only on day 0. The dose of radiotherapy was 3.6 Gy and the dose of NHS-IL2 was 5 mg/kg. Each treatment group comprised 10 mice through day 14, and 6 mice thereafter; 4 mice from each group, selected around the mean, were sacrificed on day 14 for mechanistic endpoints. The experiment was repeated 3 times with similar results. Cis, cisplatin; RTX, radiotherapy.

Back to article page